Rhythm Prescription drugs, Inc. (RYTM) Presents at Financial institution of America International Healthcare Convention 2026 Transcript

Tazeen Ahmad
BofA Securities, Analysis Division

I am Tazeen Ahmad. I am one of many senior biotech analysts right here on the financial institution. It is my pleasure to have our subsequent presenting firm, Rhythm Prescription drugs. Sitting up right here on stage with me is David Meeker, who’s, in fact, President and CEO. Welcome.

David Meeker
Chairman, President & CEO

Thanks.

Tazeen Ahmad
BofA Securities, Analysis Division

So for the few individuals who could not know in regards to the platform of the corporate, David, perhaps you can provide us a fast overview, after which we will go into some specifics.

David Meeker
Chairman, President & CEO

Positive. So Rhythm is an organization that was actually based across the melanocortin-4 pathway biology. The drug that is authorised for a number of indications is an analogue of the pure hormone that indicators by way of this melanocortin-4 receptor. And what that biology does may be very merely is once we eat a meal, our intestine hormone sign to the pancreas and to the adipocyte, the adipocyte releases leptin and it goes to the mind, indicators down by way of this a part of the hypothalamus, this POMC neuron, which then causes a hormone alpha-melanocyte-stimulating hormone to be launched.

And when that interacts with the receptor, it tells the physique you are full and there is meals on board. So you may improve your metabolic fee. So when you have impaired signaling by way of that pathway, you would possibly eat a meal otherwise you eat a meal. The physique does not get the sign, you are full, so you retain consuming. After which perversely, the physique thinks you are ravenous, it isn’t getting the indicators meals on board, and so it retains the metabolic fee low.